Bio-Techne develops and sells life science research tools, primarily proteins, antibodies, and analytical instruments. The company’s core business centers on biological reagents sold under the R&D Systems and Novus Biologicals brands, used by researchers and pharmaceutical firms to study biological processes and develop drugs. Bio-Techne also provides automated analytical instruments through its ProteinSimple brand, such as the Simple Western and Maurice platforms, to characterize and quantify proteins for research and manufacturing quality control. Additionally, the company operates a spatial biology business that provides kits and instruments for visualizing RNA and protein expression in tissue samples. Bio-Techne’s business model emphasizes a recurring revenue stream, with the vast majority of revenue derived from consumables. The company utilizes a razor-and-blade model for its instruments, placing hardware at customer sites to drive ongoing sales of cartridges and reagents. Bio-Techne’s strategy focuses on high-growth verticals like cell therapy reagents, proteomic instrumentation, and spatial biology. The company uses M&A to expand its portfolio, including the acquisition of Lunaphore and a commitment to acquire Wilson Wolf. Bio-Techne sells through a direct sales force in major markets and through distributors like Thermo Fisher Scientific. In June 2026, Bio-Techne agreed to be acquired by the German company Merck.